Japan Lifeline Co., Ltd.
7575・Prime Market・Wholesale Trade
Business
Japan Lifeline Co., Ltd., founded in 1981, is a medical device manufacturer and distributor operating primarily in the cardiovascular field, with business spanning five product categories: arrhythmia treatment (EP/Ablation, Rhythm Device), aortic disease treatment (Cardiovascular), cerebrovascular intervention, and gastroenterological disease treatment (Gastroenterology). Its main customers are general hospitals and other medical institutions in Japan, and it delivers products through its own nationwide sales network. Its consolidated subsidiary, JLL Malaysia Sdn. Bhd., manufactures EP/Ablation products and some Gastroenterology products at its Malaysian plant, and the company also has a non-consolidated subsidiary in South Korea. In FY2026 (ending March 2026), net sales were ¥59,187 million, and the company maintained a high operating margin of 21.3%.
Business Model
The company employs a hybrid business model combining proprietary products (56.0% of net sales) with products sourced from overseas manufacturers. Proprietary products are manufactured at its own factories in Saitama, Tochigi, and Malaysia, securing high gross margins, while its trading function enables the swift introduction of advanced overseas technologies into the domestic market. A nationwide proprietary sales network supports both functions, achieving a high-profitability structure with a gross profit margin of 59.4% and an operating margin of 21.3%.
Company Strengths
The company maintains a 95% market share in intracardiac defibrillation catheters, and its femoral vein hemostasis device has penetrated over 40% of all cases within two years of launch. Its proprietary product "XEROstar," launched in Q4 of FY2026 (ending March 2026), has also shown a favorable start. EP/Ablation sales reached ¥29,109 million, accounting for 49.2% of total company sales, making it a core business.
The company maintains a high 90% share in Frozen Elephant Trunk (FET), and has expanded its market share in artificial blood vessels as well, aided by other companies' reduction of their product lines. Centered on its proprietary "FROZENIX" series, the company has expanded case coverage through the addition of larger-diameter sizes. Cardiovascular sales grew steadily to ¥12,657 million (+3.7% year on year).
The operating margin for FY2026 (ending March 2026) was 21.3%, maintaining high profitability that exceeds the target level (around 20%) set in the medium-term management plan. In addition to a high gross profit structure, with a proprietary product ratio of 56.0% and a gross profit margin of 59.4%, approximately 70% of merchandise purchases are denominated in yen, limiting the impact of exchange rate fluctuations and forming a stable earnings base.
ENVALITH's Perspective
Performance Trend
Revenue grew for five consecutive fiscal years, from ¥51,469 million in FY2022 (ended March 2022) to ¥59,187 million in FY2026 (ending March 2026). In FY2026, revenue increased 4.6% year on year and operating profit increased 2.3% year on year, with both revenue and profit at each stage reaching record highs. However, gross margin declined slightly to 59.4% (down 1.0pt year on year) and operating margin to 21.3% (down 0.5pt year on year), indicating a modest deterioration in profitability. As an external factor, the increase in the number of atrial fibrillation cases (up nearly 10% year on year) supported demand, while reimbursement price revisions, a worsening product mix due to the spread of PFA, and cost increases from inflation put pressure on margins. For FY2027 (ending March 2027), revenue is expected to reach ¥63,200 million (up 6.8%), but due to a substantial increase in SG&A expenses (up 14.3% year on year), operating profit is projected to fall sharply to ¥10,700 million (down 15.1%), entering a phase of temporary deterioration in profitability.
Growth Strategy
Aiming for net sales of ¥70.0 billion in FY2028 (ending March 2028) through three pillars: expansion into new fields, continuous introduction of competitive products, and global expansion
The proprietary product "XEROstar" (a radiofrequency wire for transseptal puncture) achieved a very favorable launch following its full release in March 2026. The company also launched a sensor-equipped guidewire for TAVI and an administration catheter system for regenerative medicine products, contributing to revenue growth. In FY2027 (ending March 2027), XEROstar is expected to become a full-fledged growth driver.
In Cerebrovascular, revenue increased +44.5% year on year, driven by marketing differentiation of thrombus aspiration catheters, development of new sales channels for embolization coils, and an increase in facilities adopting stent retrievers. In Gastroenterology, revenue rose +17.4%, as biliary tube stents progressed faster than initially expected. Double-digit growth is expected to continue in both fields in FY2027 (ending March 2027).
The company is addressing, as an urgent priority, the optimization of domestic products for overseas markets and the establishment of global quality standards. It has clearly stated a policy to accelerate strategic R&D investment related to PFA and overseas market development in FY2027 (ending March 2027). While leveraging the fact that approximately 70% of merchandise procurement is yen-denominated, the company also aims to diversify domestic risk.
In response to the rapid adoption of Pulse Field Ablation (PFA), the company is increasing R&D spending on its proprietary PFA system. In FY2027 (ending March 2027), accelerated R&D expenses are factored in as one of the main drivers of increased SG&A expenses, and this is positioned as a medium- to long-term growth opportunity.
In FY2026 (ending March 2026), the company retired treasury stock (equivalent to ¥4,469 million), reducing capital surplus. The dividend was ¥54 per share (payout ratio of 40.5%), and the FY2027 (ending March 2027) forecast is ¥56 per share (payout ratio of 49.1%), maintaining a trend of dividend increases. With an equity ratio of 82.1% and ROE of 14.9%, the company maintains a balance between financial soundness and shareholder returns.
Last updated: July 19, 2026